Longevity Stocks
Track and analyze the world's leading aging research and life extension companies
# | Company | Price | Market Cap | Longevity Angle | Tags |
---|---|---|---|---|---|
1 |
![]() Vertex Pharmaceuticals Incorporated
VRTX
|
$473.3768 | $121.91B | Gene editing and age-related disease treatments | Gene Therapy Disease Treatment Biotech |
2 |
![]() Seagen Inc.
SGEN
|
$228.74 | $43.15B | Targeted therapies for age-related cancers | Cancer Antibodies Research |
3 |
![]() Alnylam Pharmaceuticals, Inc.
ALNY
|
$273.49 | $35.28B | RNA therapeutics for age-related conditions | RNA Therapeutics Research |
4 |
![]() BioNTech SE
BNTX
|
$119.955 | $28.76B | mRNA technology for age-related diseases | mRNA Therapeutics Research |
5 |
![]() BeiGene, Ltd.
BGNE
|
$184.71 | $20.21B | Novel therapeutics for age-related diseases | Cancer Therapeutics Research |
6 |
![]() Ionis Pharmaceuticals, Inc.
IONS
|
$32.55 | $5.14B | RNA-targeted therapeutics for aging diseases | RNA Drug Development Research |
7 |
![]() CRISPR Therapeutics AG
CRSP
|
$40.79 | $3.48B | CRISPR gene editing for age-related diseases | Gene Editing CRISPR Therapeutics |
8 |
![]() Denali Therapeutics Inc.
DNLI
|
$22.52 | $3.24B | Neurodegenerative disease treatments | Neurodegeneration Brain Health Research |
9 |
![]() Beam Therapeutics Inc.
BEAM
|
$27.72 | $2.30B | Base editing technology for genetic diseases | Base Editing Genetics Research |
10 |
![]() Verve Therapeutics, Inc.
VERV
|
$8.43 | $713.72M | Gene editing for cardiovascular disease | Gene Editing Heart Disease Research |
11 |
![]() Sage Therapeutics, Inc.
SAGE
|
$7.24 | $442.89M | Brain health and aging-related disorders | Brain Health Neuroscience Research |
12 |
![]() Allogene Therapeutics, Inc.
ALLO
|
$1.58 | $331.28M | Allogeneic cell therapy for longevity | Cell Therapy Cancer Research |
13 |
![]() Fate Therapeutics, Inc.
FATE
|
$1.35 | $153.76M | Cell therapy for regenerative medicine | Cell Therapy Regenerative Research |
14 |
![]() Editas Medicine, Inc.
EDIT
|
$1.285 | $106.07M | Gene editing platform for age-related conditions | Gene Editing Therapeutics Research |
15 |
![]() bluebird bio, Inc.
BLUE
|
$6.6 | $64.17M | Gene therapy for age-related conditions | Gene Therapy Rare Disease Research |
16 |
![]() Longeveron Inc.
LGVN
|
$1.62 | $24.04M | Regenerative medicine and anti-aging research | Regenerative Anti-aging Research |
17 |
![]() Frequency Therapeutics, Inc.
FREQ
|
$0.2996 | $10.94M | Regenerative medicine for hearing loss | Regenerative Hearing Research |
18 |
![]() Applied Genetic Technologies Corporation
AGTC
|
$0.3936 | $- | Gene therapy for age-related eye diseases | Gene Therapy Eye Disease Research |
VRTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Vertex Pharmaceuticals Incorporated
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week treatment period and additional long-term follow-up of its investigational therapeutic tividenofusp alfa (DNL310). These data, along with recent Breakthrough Therapy designation, further support the company's plan to submit a biologics license application (BLA) in early 2025 for accelerated approval and deliver this potential treatment to the Hunter syndrome community in late 2025 or early 2026. The Phase 1/2 results are being presented this week at the 21st Annual WORLDSymposium™ conference in San Diego, California.

ATTENTION VRTX SHAREHOLDERS: Investors who Lost Money on Vertex Pharmaceuticals Incorporated are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay And thank you for joining Guggenheim during our second SMID Cap conference. I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni.

Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized treatment centers for Casgevy and advancing multiple drug candidates in hemoglobinopathies, CAR-T, and in vivo programs.

Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

An Investigation Has Commenced on Behalf of Vertex Pharmaceuticals Incorporated Shareholders. Contact Levi & Korsinsky to Discuss your VRTX Losses.
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Ionis to hold fourth quarter and full year 2024 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that b.

VRTX STOCK ALERT: Levi & Korsinsky Notifies Vertex Pharmaceuticals Incorporated Investors of an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals (VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company granted equity awards to eight new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Lost Money on Vertex Pharmaceuticals Incorporated(VRTX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (VRTX 5.31%) are down about 9% from a peak the stock set in November, despite some highly positive news.

Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential. Phase 2 LSR trial showed minimal benefit vs placebo, raising concerns about $11B peak sales estimates and success in ongoing diabetic neuropathy trial (completion in 2027). Conservative market expectations: Acute pain market $10-20B; $1.5B sales (10% share) more realistic. Must compete with established generics in neuropathic pain market.

Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine
Expectation is a decline in Vertex's earnings, but double-digit revenue growth should continue with the newly approved non-opioid drug JOURNAVX and CF franchise expansion. JOURNAVX, the first non-opioid oral pain signal inhibitor approved in over 20 years, targets a large market, potentially boosting Vertex's revenue significantly over time. The company's CF franchise continues to expand with new approvals and treatments, including TRIKAFTA, ALYFTREK, and VX-522, targeting a broader patient base.

Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
JOURNAVX, a non-opioid analgesic, shows significant promise in treating pain with a superior safety profile, addressing a critical unmet need compared to opioids with FDA approval just announced. Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside.

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Verve Therapeutics, Inc. (NASDAQ: VERV) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Vertex Pharmaceuticals CEO on non-opioid painkiller: It's safe, effective and non-addictive
CNBC's Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the FDA's approval of the company's non-opioid painkiller pill Journavx, a new alternative for pain relief that comes without the risk of addiction, concerns around drug effectiveness and costs, and more.

Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY's use in the NHS. It means that eligible SCD patients in England now have access to the therapy follo.

FDA Approves Non-Opioid Painkiller With No Addiction Risk
The Food and Drug Administration approved Vertex Pharmaceuticals' “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA considered the start of a new class of non-addictive medicines.

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. “Today's approval is a histori.

FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. It's a milestone after a long history of unsuccessful efforts to develop painkillers without the destructive dependency of opioids, which have caused a horrific epidemic in the U.S.

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2024 results as well as expectations for the future via conference call on Thursday, February 13, 2025 at 8.

Investors who Lost Money on Vertex Pharmaceuticals Incorporated Should Contact Levi & Korsinsky About an Ongoing Investigation - VRTX
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:30 p.m. ET in New York.

VRTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Vertex Pharmaceuticals Incorporated
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York.

Frequently Asked Questions
- Age-Related Disease Treatment - Targeting specific diseases of aging
- Cellular Reprogramming - Reversing cellular aging processes
- Gene Therapy - Modifying genes to extend lifespan
- Regenerative Medicine - Repairing or replacing aged tissues
- Aging Biomarkers - Measuring biological age and interventions
- VRTX - Vertex Pharmaceuticals Incorporated
- SGEN - Seagen Inc.
- ALNY - Alnylam Pharmaceuticals, Inc.
- BNTX - BioNTech SE
- BGNE - BeiGene, Ltd.
- Senescent Cell Removal - Clearing aged, damaged cells
- NAD+ Boosters - Enhancing cellular energy production
- Stem Cell Therapy - Regenerating tissues and organs
- Epigenetic Reprogramming - Resetting cellular age
- Mitochondrial Enhancement - Improving cellular powerhouses
- Telomere Extension - Protecting chromosome ends
- Aging global population and healthcare demands
- Breakthrough technologies in aging research
- Growing private and public funding
- Potential for revolutionary treatments
- Multiple revenue streams (therapeutics, diagnostics, data)
- Clinical trial results and FDA approvals
- Research breakthroughs and patents
- Partnership deals with major pharma
- Regulatory environment for aging therapies
- Healthcare policy and reimbursement
- Competition and technological advances